Anti-Human CD22 VHH (SAA2691)
A highly specific and effective tool for biotech research.
This innovative product is a recombinant single-domain antibody, also known as VHH, that targets the human CD22 protein. CD22 is a cell surface receptor found on B cells and plays a crucial role in regulating immune response.
The main function of Anti-Human CD22 VHH is to bind to CD22 and block its activity, leading to the inhibition of B cell activation and proliferation. This makes it an ideal tool for studying the role of CD22 in various biological processes, including autoimmune diseases, cancer, and immunodeficiency.
Anti-Human CD22 VHH has a wide range of applications in biotech research. It can be used in in vitro studies to investigate the function of CD22 in different cell types and disease models. It is also suitable for in vivo studies, as it has been shown to effectively target CD22 in animal models.
One of the key advantages of Anti-Human CD22 VHH is its high specificity and low off-target binding. This ensures accurate and reliable results, making it a valuable tool for drug discovery and development. Additionally, its small size and high stability make it suitable for a variety of experimental techniques, including flow cytometry, Western blotting, and immunohistochemistry.
Researchers can also use Anti-Human CD22 VHH to develop novel therapies targeting CD22. By understanding the role of CD22 in disease, this product can aid in the development of more targeted and effective treatments for conditions such as B cell malignancies and autoimmune disorders.
In summary, Anti-Human CD22 VHH (SAA2691) is a cutting-edge product that offers a specific and versatile approach to studying CD22 in biotech research. With its high specificity, stability, and potential for therapeutic development, it is a valuable asset for any research laboratory. Order now and take your research to the next level.
There are no reviews yet.